OC CONTRIBUTES TO MAJOR JOURNAL

July 8, 2015

Oncology Consultants contributed to an important safety study of Nivolumab (Opdivo), published in The Lancet Oncology, March the 1st 2015. This new drug has a meaningful and manageable safety profile in previously treated patients with advanced, refractory, squamous nonsmall cell lung cancer. The FDA approved Nivolumab, a fully human IgG4 PD-1 immune check inhibitor antibody, for this indication.

 

 

The Doctors & Staff of Oncology Consultants are pleased to help advance oncology treatments from research to practice through our participation in the Checkmate Protocol. (NCT01721759).

 

 

Share on Facebook
Share on Twitter
Please reload

Recent Posts
Please reload

Archive
Please reload

CONTACT

!

Your feedback is important. If this

is an urgent matter, please contact your clinic. For all other inquiries, please...

QUICK LINKS

  • Facebook Social Icon
  • Twitter Social Icon
  • Instagram Social Icon
  • LinkedIn Social Icon
  • YouTube Social  Icon

The Oncology Consultants Overcoming Cancer

logo is a registered trademark.

Texas Medical Center
2130 W. Holcombe Blvd., 10th Fl.
Houston, TX 77030
Memorial City
925 Gessner Rd., Ste. 600
Houston, TX 77024
Katy
23960 Katy Freeway, Ste. 325
Katy, TX 77494
Sugar Land
16605 Southwest Frwy, Ste. 550
Sugar Land, TX 77479
Greater Heights 
1631 North Loop West, Ste. 410
Houston, TX 77008
Southeast
11920 Astoria Boulevard, Ste. 150
Houston, TX 77089
Willowbrook
13215  Dotson Rd., Ste. 340
Houston, TX 77070
Southwest
7789 Southwest Fwy, Ste. 460
Houston, TX 77074
Pearland
1920 Country Pl. Pwy, Ste. 370
Pearland, TX 77584
Precision Cancer Center
10405 Katy Freeway, Ste. 150E
Houston, TX 77024